Shedding of ctDNA, radiomics assessment of tumor disease volume (TDV), and concordance of mutations (mut) in synchronous liquid and tumor biopsies in metastatic breast cancer (MBC).

被引：0

作者：

Papakonstantinou, Andri

Gonzalez-Medina, Alberto

Matito, Judit

Ligero, Marta

Ruiz-Pace, Fiorella

Sunol, Anna

Rivero, Joaquin

Fasani, Roberta

Cruellas, Mara

Peg, Vicente

Borrell, Maria

Pimentel, Isabel

Munoz, Santiago Escriva De Romani

Gelpi, Judith Balmana

Nuciforo, Paolo

Dienstmann, Rodrigo

Saura, Cristina

Perez-Lopez, Raquel

Oliveira, Mafalda

Vivancos, Ana

机构：

[1] Karolinska Inst & Breast Canc Grp, Vall Hebron Inst Oncol VHIO, Dept Oncol Pathol, Barcelona, Spain

[2] Vall Hebron Inst Oncol VHIO, Canc Genom Grp, Barcelona, Spain

[3] Vall Hebron Inst Oncol VHIO, Radi Grp, Barcelona, Spain

[4] Vall Hebron Inst Oncol VHIO, Oncol Data Sci ODysSey Grp, Barcelona, Spain

[5] Vall Hebron Inst Oncol VHIO, Breast Canc Grp, Barcelona, Spain

[6] Vall dHebron Univ Hosp, Breast Canc Ctr, Breast Surg Unit, Barcelona, Spain

[7] Vall Hebron Inst Oncol VHIO, Mol Oncol Grp, Barcelona, Spain

[8] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Med Oncol Dept & Breast Canc Grp, Barcelona, Spain

[9] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain

[10] Vall dHebron Inst Oncol, Clin Canc Genet & Breast Canc Grp, Barcelona, Spain

[11] Vall Hebron Inst Oncol, Barcelona, Spain

[12] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1086

引用

页数：1

共 50 条

[1] Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC).
Oliveira, Mafalda
Ruiz-Pace, Fiorella
Matito, Judit
Perez-Lopez, Raquel
Sunol, Anna
Bellet, Meritxell
Escriva-de-Romani, Santiago
Zamora, Esther
Gomez, Patricia
Garrigos, Laia
Capelan, Marta
Arumi, Miriam
Ortiz, Carolina
Amair-Pinedo, Fabiola
Mancuso, Francesco M.
Espinosa-Bravo, Martin
Nuciforo, Paolo
Dienstmann, Rodrigo
Vivancos, Ana
Saura, Cristina
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[2] Concordance of genomic alterations (GA) in synchronous tumor biopsies (tBx) and circulating tumor (ct) DNA from metastatic breast cancer (MBC) patients (pts).
Oliveira, Mafalda
Bellet, Meritxell
Sunol, Anna
Ruiz-Pace, Fiorella
Gomez, Patricia
Escriva, Santiago
Garrigos, Laia
Zamora, Esther
Capelan, Marta
Azaro, Analia
Arumi, Miriam
Ortiz, Carolina
Matito, Judit
Fasani, Roberta
Mancuso, Francesco M.
Espinosa, Martin
Nuciforo, Paolo
Dienstmann, Rodrigo
Vivancos, Ana
Saura, Cristina
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] Circulating tumor DNA (ctDNA) as a molecular monitoring tool in metastatic breast cancer (MBC)
Austin, Laura Katherine
Fortina, Paolo
Sebisanovic, Dragan
Siew, LaiMun
Zapanta, Aubrey
Talasaz, AmirAli
Cristofanilli, Massimo
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[4] Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) longitudinal monitoring of metastatic breast cancer (MBC).
Costa, Ricardo Lima Barros
Rossi, Giovanna
Mu, Zhaomei
Austin, Laura Katherine
Rademaker, Alfred
Gradishar, William John
Santa-Maria, Cesar Augusto
Jain, Sarika
Flaum, Lisa E.
Giles, Francis J.
Yang, Hushan
Cristofanilli, Massimo
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] Concordance of circulating tumor DNA (ctDNA) and next-generation sequencing (NGS) as molecular monitoring tools in metastatic breast cancer (MBC)
Austin, Laura K.
Avery, Tiffany
Jaslow, Rebecca
Fortina, Paolo
Sebisanovic, Dragan
Siew, LaiMun
Zapanta, Aubrey
Talasaz, AmirAli
Cristofanilli, Massimo
CANCER RESEARCH, 2015, 75
[6] ESR1 mutations in circulating tumor DNA (ctDNA) are associated with CTCs and increased hormone receptors in metastatic tumor tissues of patients with metastatic breast cancer (MBC).
Zhang, Qiang
Qin, Weijun
D'Amico, Paolo
Jiao, Jianhua
Davis, Andrew A.
Gerratana, Lorenzo
Donahue, Jeannine
Reduzzi, Carolina
Manai, Marwa
Jacob, Saya
Zhang, Youbin
Flaum, Lisa E.
Behdad, Amir
Cristofanilli, Massimo
Platanias, Leonidas C.
Shah, Ami N.
Gradishar, William John
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[7] Dynamic development of ESR1 mutations in circulating tumor DNA (ctDNA) is associated with prognosis of patients with metastatic breast cancer (MBC)
Zhang, Qiang
Jiao, Jianhua
Gerratana, Lorenzo
D'Amico, Paolo
Singhal, Seema
Zhang, Youbin
Davis, Andrew A.
Shah, Ami N.
Gradishar, William
CANCER RESEARCH, 2023, 83 (07)
[8] Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC).
Pusztai, Lajos
Chung, Jon
Young, Lauren
Schrock, Alexa Betzig
Hartmaier, Ryan
Frampton, Garrett Michael
Gay, Laurie M.
Stephens, Phil
Miller, Vincent A.
Ali, Siraj Mahamed
Ross, Jeffrey S.
Vahdat, Linda T.
O'Shaughnessy, Joyce
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] Genomic progression, detected by circulating tumor DNA (ctDNA) sequencing, as an early predictor of disease progression in metastatic breast cancer (MBC)
Velimirovic, M.
Juric, D.
Niemierko, A.
Spring, L. M.
Vidula, N.
Malvarosa, G.
Yuen, M.
Moy, B.
Isakoff, S. J.
Ellisen, L. W.
Bardia, A.
CANCER RESEARCH, 2019, 79 (04)
[10] Circulating tumor DNA (ctDNA) sequencing for HER2 mutation (HER2mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC)
Ma, Cynthia
Bose, Ron
Gao, Feng
Freedman, Rachel
Telli, Melinda
Kimmick, Gretchen
Winer, Eric
Naughton, Michael
Goetz, Matthew
Russell, Christy
Tripathy, Debu
Cobleigh, Melody
Forero, Andres
Pluard, Timothy
Anders, Carey
Thomas, Shana
Anderson, Jill
Bumb, Caroline
Banks, Kimberly
Lanman, Richard
Bryce, Richard
Lalani, Alshad
Pfeifer, John
Hays, Daniel
Pegram, Mark
Blackwell, Kimberly
Bedard, Philippe
Al-Kateb, Hussam
Ellis, Matthew
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →